Nicolò Bizzarri1, Luigi Pedone Anchora1, Gian Franco Zannoni2,3, Vittoria Carbone1, Matteo Bruno1, Camilla Fedele1, Valerio Gallotta1, Vito Chiantera4, Giacomo Avesani5, Benedetta Gui5, Francesco Fanfani1,3, Anna Fagotti1,3, Giovanni Scambia6,7, Gabriella Ferrandina1,3. 1. Fondazione Policlinico Universitario A. Gemelli, IRCCS, UOC Ginecologia Oncologica, Dipartimento per la Salute della Donna e del Bambino e della Salute Pubblica, Rome, Italy. 2. Fondazione Policlinico Universitario A. Gemelli, IRCCS, Gyneco-pathology and Breast Pathology Unit, Dipartimento per la salute della Donna e del Bambino e della Salute Pubblica, Rome, Italy. 3. Università Cattolica del Sacro Cuore, Rome, Italy. 4. ARNAS Ospedali Civico Di Cristina Benfratelli, Department of Gynecologic Oncology, University of Palermo, Palermo, Italy. 5. Fondazione Policlinico Universitario A. Gemelli, IRCCS, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Rome, Italy. 6. Fondazione Policlinico Universitario A. Gemelli, IRCCS, UOC Ginecologia Oncologica, Dipartimento per la Salute della Donna e del Bambino e della Salute Pubblica, Rome, Italy. giovanni.scambia@policlinicogemelli.it. 7. Università Cattolica del Sacro Cuore, Rome, Italy. giovanni.scambia@policlinicogemelli.it.
Abstract
BACKGROUND: The aim of the present study was to assess the prognostic value of tumour-free distance (TFD), defined as the minimum distance of uninvolved stroma between the tumour and peri-cervical stromal ring, in early-stage cervical cancer. METHODS: Patients with pathologic FIGO 2009 stage IA1-IIA2 cervical cancer, treated by primary radical surgical treatment between 01/2000 and 11/2019, were retrospectively included. Adjuvant treatment was administered according to the presence of previously established pathologic risk factors. TFD was measured histologically on the hysterectomy specimen. Pre-operative TFD measured at MRI-scan from a cohort of patients was reviewed and compared with pathology TFD. RESULTS: 395 patients were included in the study. 93 (23.5%) patients had TFD ≤ 3.0 mm and 302 (76.5%) had TFD > 3.0 mm. TFD ≤ 3.0 mm together with lymph vascular space involvement represented the strongest predictor for lymph node metastasis at multivariate analysis. TFD ≤ 3.0 mm was associated with worse 5-year disease-free survival (DFS) and overall survival (OS), compared with TFD > 3.0 mm (p = 0.022 and p = 0.008, respectively). DFS difference was more evident in the subgroup of patients with low-risk factors who did not receive adjuvant treatment (p = 0.002). Cohen's kappa demonstrated an agreement between TFD measured at pre-operative MRI-scan and histology of 0.654. CONCLUSIONS: Pathologic TFD ≤ 3.0 mm represents a poor prognostic factor significantly associated with lymph node metastasis and it may be considered a novel marker to select candidates for adjuvant treatment. The possibility to obtain this parameter by radiological imaging makes it a potential easy-measurable pre-operative marker to predict the presence of high-risk pathologic factors in early-stage cervical cancer.
BACKGROUND: The aim of the present study was to assess the prognostic value of tumour-free distance (TFD), defined as the minimum distance of uninvolved stroma between the tumour and peri-cervical stromal ring, in early-stage cervical cancer. METHODS: Patients with pathologic FIGO 2009 stage IA1-IIA2 cervical cancer, treated by primary radical surgical treatment between 01/2000 and 11/2019, were retrospectively included. Adjuvant treatment was administered according to the presence of previously established pathologic risk factors. TFD was measured histologically on the hysterectomy specimen. Pre-operative TFD measured at MRI-scan from a cohort of patients was reviewed and compared with pathology TFD. RESULTS: 395 patients were included in the study. 93 (23.5%) patients had TFD ≤ 3.0 mm and 302 (76.5%) had TFD > 3.0 mm. TFD ≤ 3.0 mm together with lymph vascular space involvement represented the strongest predictor for lymph node metastasis at multivariate analysis. TFD ≤ 3.0 mm was associated with worse 5-year disease-free survival (DFS) and overall survival (OS), compared with TFD > 3.0 mm (p = 0.022 and p = 0.008, respectively). DFS difference was more evident in the subgroup of patients with low-risk factors who did not receive adjuvant treatment (p = 0.002). Cohen's kappa demonstrated an agreement between TFD measured at pre-operative MRI-scan and histology of 0.654. CONCLUSIONS: Pathologic TFD ≤ 3.0 mm represents a poor prognostic factor significantly associated with lymph node metastasis and it may be considered a novel marker to select candidates for adjuvant treatment. The possibility to obtain this parameter by radiological imaging makes it a potential easy-measurable pre-operative marker to predict the presence of high-risk pathologic factors in early-stage cervical cancer.
Authors: Marloes Derks; Jacobus van der Velden; Cornelis D de Kroon; Hans W Nijman; Luc R C W van Lonkhuijzen; Ate G J van der Zee; Aeilko H Zwinderman; Gemma G Kenter Journal: Int J Gynecol Cancer Date: 2018-05 Impact factor: 3.437
Authors: David Cibula; Richard Pötter; François Planchamp; Elisabeth Avall-Lundqvist; Daniela Fischerova; Christine Haie Meder; Christhardt Köhler; Fabio Landoni; Sigurd Lax; Jacob Christian Lindegaard; Umesh Mahantshetty; Patrice Mathevet; W Glenn McCluggage; Mary McCormack; Raj Naik; Remi Nout; Sandro Pignata; Jordi Ponce; Denis Querleu; Francesco Raspagliesi; Alexandros Rodolakis; Karl Tamussino; Pauline Wimberger; Maria Rosaria Raspollini Journal: Int J Gynecol Cancer Date: 2018-05 Impact factor: 3.437
Authors: Aaron H Wolfson; Mahesh A Varia; David Moore; Gautam G Rao; David K Gaffney; Beth A Erickson-Wittmann; Anuja Jhingran; Nina A Mayr; Ajmel A Puthawala; William Small; Catheryn M Yashar; William Yuh; Higinia Rosa Cardenes Journal: Gynecol Oncol Date: 2011-12-07 Impact factor: 5.482
Authors: Andrea Diaz De Vivar; Andres A Roma; Kay J Park; Isabel Alvarado-Cabrero; Golnar Rasty; Jose G Chanona-Vilchis; Yoshiki Mikami; Sung R Hong; Brent Arville; Norihiro Teramoto; Rouba Ali-Fehmi; Joanne K L Rutgers; Farah Tabassum; Denise Barbuto; Irene Aguilera-Barrantes; Alexandra Shaye-Brown; Dean Daya; Elvio G Silva Journal: Int J Gynecol Pathol Date: 2013-11 Impact factor: 2.762
Authors: Marc Arbyn; Elisabete Weiderpass; Laia Bruni; Silvia de Sanjosé; Mona Saraiya; Jacques Ferlay; Freddie Bray Journal: Lancet Glob Health Date: 2019-12-04 Impact factor: 26.763
Authors: David Cibula; Jiri Slama; Lukáš Dostálek; Daniela Fischerová; Anna Germanova; Filip Frühauf; Pavel Dundr; Kristyna Nemejcova; Jiri Jarkovsky; Silvie Sebestova; Andrea Burgetová; Martina Borčinová; Roman Kocián Journal: Br J Cancer Date: 2020-12-14 Impact factor: 7.640